<div id="readability-page-1">Seaport Therapeutics (SPTX) on Monday filed for an initial public offering of 11.8M shares priced between $16 and $18 each, seeking to raise as much as about $212M. At $18 per share, the clinical-stage biotech firm will have a market value of $912M. The company has applied to list its shares on the Nasdaq Global Market under the ticker SPTX. Goldma...</div>

PRTC

PRTCY

<p>Seaport Therapeutics (SPTX) has filed for an IPO to raise up to $212M by offering 11.8M shares priced between $16 and $18 each. The company, focused on developing oral therapies for neuropsychiatric diseases, aims for a market value of $912M at the top share price. Goldman Sachs, JP Morgan, and Leerink Partners are leading the offering. Seaport reported a net loss of $74.9M last year and is backed by PureTech Health, which owns nearly 50% of the company.</p>

PureTech Health

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS

Nasdaq

Goldman Sachs

GS Hldg R

Drug developer Seaport Therapeutics seeks up to $212M in US IPO